• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Fractyl Health Inc.

    10/14/25 4:42:38 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care
    Get the next $GUTS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    FRACTYL HEALTH, INC.

    (Name of Issuer)


    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)


    35168W103

    (CUSIP Number)


    10/10/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    683 Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,125,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,125,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,125,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.33 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    683 Capital Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,125,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,125,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,125,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.33 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Ari Zweiman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,125,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,125,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,125,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.33 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    FRACTYL HEALTH, INC.
    (b)Address of issuer's principal executive offices:

    3 Van de Graaff Drive, Suite 200, Burlington, MASSACHUSETTS 01803
    Item 2. 
    (a)Name of person filing:

    683 Capital Management, LLC 683 Capital Partners, LP Ari Zweiman Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, New York 10019.
    (c)Citizenship:

    683 Capital Management, LLC - DELAWARE 683 Capital Partners, LP - DELAWARE Ari Zweiman - UNITED STATES
    (d)Title of class of securities:

    Common Stock, $0.00001 par value per share
    (e)CUSIP No.:

    35168W103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of October 14, 2025, 683 Capital Partners, LP beneficially owned (i) 5,220,240 shares of Common Stock and (ii) warrants to purchase 1,904,760 shares of Common Stock which are currently exercisable. 683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the (i) 5,220,240 shares of Common Stock and (ii) warrants to purchase 1,904,760 shares of Common Stock which are currently exercisable beneficially owned by 683 Capital Partners, LP. Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned (i) 5,220,240 shares of Common Stock and (ii) warrants to purchase 1,904,760 shares of Common Stock which are currently exercisable beneficially owned by 683 Capital Management, LLC. The following percentage is based on 131,822,552 shares of Common Stock outstanding following the completion of the offering described in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) filed on September 26, 2025 plus 1,904,760 shares of Common Stock issuable upon exercise of currently exercisable warrants held by the Reporting Persons. As of October 14, 2025, the Reporting Persons may be deemed to have beneficially owned 7,125,000 shares of Common Stock, constituting approximately 5.33% of the outstanding shares of Common Stock.
    (b)Percent of class:

    5.33  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit A.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    683 Capital Management, LLC
     
    Signature:Ari Zweiman
    Name/Title:Managing Member
    Date:10/14/2025
     
    683 Capital Partners, LP
     
    Signature:Ari Zweiman
    Name/Title:Authorized Person
    Date:10/14/2025
     
    Ari Zweiman
     
    Signature:Ari Zweiman
    Name/Title:Self
    Date:10/14/2025
    Exhibit Information

    JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G dated October 14, 2025 with respect to the Common Stock, par value $0.00001 per share, of Fractyl Health Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. 683 CAPITAL MANAGEMENT, LLC By: /s/ Ari Zweiman Ari Zweiman, Managing Member Date: 10/14/2025 683 CAPITAL PARTNERS, LP By: /s/ Ari Zweiman Ari Zweiman, Authorized Person Date: 10/14/2025 ARI ZWEIMAN By: /s/ Ari Zweiman Ari Zweiman, Self Date: 10/14/2025

    Get the next $GUTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    9/15/2025$9.00Buy
    H.C. Wainwright
    8/28/2025$3.60Buy
    Ladenburg Thalmann
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

    RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced potent new preclinical data from RJVA-002, the second candidate from the Company's Rejuva® Smart GLP-1™ platform, at the 2025 Cell & Gene Mee

    10/7/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

    Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ: GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are being offered by Fractyl. The gross proceeds from the offering to Fractyl are expected to be approximately $60 million, before deducting underwriting discounts and commissions and other offering ex

    9/26/25 7:05:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

    Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients Revita procedure demonstrated excellent safety and tolerability to date, consistent with prior clinical studies Results validate pivotal study design and reinforce Revita's potential to be the first therapy for post-GLP-1 weight maintenance Company to host investor call and webcast today at 8:00 a.m. ET BURLINGTON, Mass., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pa

    9/26/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 7:57:09 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 4:50:44 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Schulman Amy W bought $9,964 worth of shares (8,550 units at $1.17) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/17/25 5:09:08 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Thompson Christopher Charles

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    9/4/25 8:36:12 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Thompson Christopher Charles

    3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    9/4/25 8:26:56 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Sheffield Ian

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    9/4/25 8:07:54 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Fractyl Health with a new price target

    H.C. Wainwright initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $9.00

    9/15/25 8:08:19 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on Fractyl Health with a new price target

    Ladenburg Thalmann initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $3.60

    8/28/25 8:09:13 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Fractyl Health

    Evercore ISI initiated coverage of Fractyl Health with a rating of Outperform

    2/28/24 8:22:09 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Fractyl Health Inc.

    SCHEDULE 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    10/14/25 4:42:38 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    10/3/25 4:05:27 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Fractyl Health Inc.

    424B5 - FRACTYL HEALTH, INC. (0001572616) (Filer)

    9/26/25 5:05:17 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Financials

    Live finance-specific insights

    View All

    Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

    BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the conference call and presentatio

    8/6/25 4:05:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

    REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

    5/13/25 4:05:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

    BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

    5/6/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Leadership Updates

    Live Leadership Updates

    View All

    Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

    BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

    4/2/24 8:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

    LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

    2/20/24 8:38:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/14/24 4:30:50 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/13/24 5:17:27 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

    2/16/24 9:43:25 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care